We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+0.61%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$413M
AUM Growth
-$90.6M
Cap. Flow
-$16.2M
Cap. Flow %
-3.92%
Top 10 Hldgs %
90.55%
Holding
26
New
2
Increased
7
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$2.82M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$2.6M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$1.75M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.32M
5
EPZM
Epizyme, Inc
EPZM
+$565K

Top Sells

Rank Stock Value
1
MZOR
Mazor Robotics Ltd.
MZOR
+$65.6M
2
AXDX
Accelerate Diagnostics
AXDX
+$4.46M
3
AMRN
Amarin Corp
AMRN
+$4.18M
4
TSRO
TESARO, Inc.
TSRO
+$2.99M
5
QDEL icon
QuidelOrtho
QDEL
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 95.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.14B
$121M 29.33%
2,336,448
-52,100
-2% -$2.43M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$102M 24.62%
444,762
-16,972
-4% -$4.46M
TSRO
3
DELISTED
TESARO, Inc.
TSRO
$48.3M 11.69%
844,718
-46,524
-5% -$2.99M
PACB icon
4
Pacific Biosciences
PACB
$432M
$19.6M 4.74%
9,537,661
+1,084,286
+13% +$2.82M
AMRN
5
Amarin Corp
AMRN
$293M
$15.6M 3.78%
258,824
-56,341
-18% -$4.18M
MZOR
6
DELISTED
Mazor Robotics Ltd.
MZOR
$15.1M 3.66%
246,317
-1,046,459
-81% -$65.6M
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
$14.9M 3.62%
1,330,070
+297,349
+29% +$2.6M
VRML
8
DELISTED
Vermillion, Inc.
VRML
$13.4M 3.24%
9,825,289
– –
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$12.5M 3.04%
2,469
– –
OPK icon
10
Opko Health
OPK
$1.25B
$11.7M 2.83%
3,686,194
-140,566
-4% -$566K
AGEN
11
Agenus
AGEN
$275M
$7.29M 1.77%
78,840
– –
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$7.04M 1.7%
396,325
+33,433
+9% +$565K
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.89M 1.67%
174,525
+33,859
+24% +$1.32M
CFRX
14
DELISTED
ContraFect Corporation
CFRX
$5.15M 1.25%
3,959
+333
+9% +$411K
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$4.33M 1.05%
159,204
– –
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.22M 0.54%
+47,696
New +$1.75M
QDEL icon
17
CALL
QuidelOrtho
QDEL
$1.14B
$2.15M 0.52%
198,300
+93,500
+89% +$4.35M
BIIB icon
18
Biogen
BIIB
$30.4B
$1.74M 0.42%
6,368
– –
BMY icon
19
CALL
Bristol-Myers Squibb
BMY
$130B
$1.2M 0.29%
+776,900
New +$50M
AXDX
20
CALL
DELISTED
Accelerate Diagnostics
AXDX
$910K 0.22%
51,640
+24,140
+88% +$6.34M
VANI icon
21
Vivani Medical
VANI
$113M
$98K 0.02%
2,117
– –
ARAY icon
22
Accuray
ARAY
$29M
– –
-376,799
Closed -$1.62M
PGEN icon
23
Precigen
PGEN
$1.97B
– –
-195,000
Closed -$2.25M
ELGX
24
DELISTED
Endologix Inc
ELGX
– –
-36,273
Closed -$1.94M
NXTM
25
CALL
DELISTED
NxStage Medical Inc.
NXTM
– –
-142,800
Closed -$4K
1
2

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q1 2018 Portfolio in Review

As of Q1 2018, Oracle Investment Management held 26 positions worth $413M, down 18% from $503M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Oracle Investment Management withdrew a net $16.2M in Q1 2018, closing 5 positions and reducing 6 holdings. Its most notable exit was Precigen, an estimated $2.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier.

Against the trend, Oracle Investment Management opened a new position in Chinook Therapeutics, Inc. Common Stock worth $2.22M.

  • Oracle Investment Management's largest Q1 2018 buy was Chinook Therapeutics, Inc. Common Stock: 47,696 shares worth $2.22M.
  • Oracle Investment Management added most to Pacific Biosciences in Q1 2018, an estimated $2.82M increase.
  • Oracle Investment Management's biggest Q1 2018 reduction was Mazor Robotics Ltd., cutting an estimated $65.6M.
  • Oracle Investment Management fully exited Precigen in Q1 2018, selling an estimated $2.25M.
  • Oracle Investment Management's ten largest holdings make up 91% of its $413M portfolio in Q1 2018.
  • Oracle Investment Management opened 2 new positions and closed 5 in Q1 2018.
  • Oracle Investment Management's portfolio value fell 18% quarter-over-quarter to $413M.

Based on Oracle Investment Management's 13F filing for Q1 2018, filed 15 May 2018.